Skip to main content

The Supreme Cannabis Company Inc (FIRE-T) Quote

Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Price Quote as of

Today's Trading

Day Low 0.83
Day High 0.93
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

The Supreme Cannabis Co Inc is a Canada based company engaged in the production and sale of medical and recreational cannabis. The company is a cultivator and distributor of cannabis through its wholly-owned subsidiary 7ACRES. Its other brands include BlissCo, Truverra, Supreme Heights, Cambium, KKE, Medigrow and PAX.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

CBD Demand Soars With a Growing Number of Uses
- PR Newswire - Tue Oct 15, 8:00AM CDT
PR Newswire - CMTX
Tue Oct 15, 8:00AM CDT
As the medical industry continues to evolve, researchers are actively looking for innovative remedies and treatments for patients. Notably, cannabis has become the topic of discussion after numerous researchers and institutions highlighted its therapeutic benefits. However, despite medical advancements throughout the cannabis industry, most federal regulators around the world have not yet moved to fully legalize cannabis for medical applications because of the psychotropic effects associated with it. Nevertheless, several regulators have decided to legalize cannabidiol, or CBD, a compound found within cannabis. CBD is a derivative found within the cannabis plant, however, unlike its tetrahydrocannabinol, or THC, counterpart, it does not induce psychoactive effects. Consequently, regulators became more inclined to legalize CBD. Primarily, the CBD industry is being accelerated by the healthcare segment. Specifically, countries such as Australia, Canada, France, Germany, Italy, the U.K. and the U.S. have all adopted CBD-related legislation. Overall, the therapeutic grade segment dominates that overall CBD market because of increasing demand from innumerable applications. The segment accounted for 58.6% of the overall CBD market share and is expected to continue its dominance. In particular, the healthcare segment is expected to account for a total of USD 10.28 Billion of the CBD market by 2026. Moreover, the food and beverage industry is also expected to witness exponential growth. And while the U.S. and Canada are the primary drivers for the global CBD market, other international markets are also expected to greatly contribute. For instance, the Asia Pacific market is anticipated to reach USD 3.1 Billion by 2026 and exhibit a CAGR of 29.5%, while the European market is projected to grow at a CAGR of 28.9%. As a result, the global cannabidiol market is expected to grow from USD 1.04 Billion in 2018 to USD 16.32 Billion by 2026 while registering a CAGR of 27.7% during the forecast period, according to data compiled by Reports and Data. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), The Green Organic Dutchman Holdings Ltd. (OTC: TGODF) (TSX: TGOD), The Supreme Cannabis Company, Inc. (OTC: SPRWF) (TSX: FIRE), Aleafia Health Inc. (OTC: ALEAF) (TSX: ALEF)
Regulators Strive to Limit Illicit Cannabis Trade as the Industry Continues its Expansion
- PR Newswire - Thu Oct 10, 8:00AM CDT
PR Newswire - CMTX
Thu Oct 10, 8:00AM CDT
Most regions around the world allow young adults at the age of 18 to enjoy or purchase their own alcohol and tobacco. However, the U.S. has strictly enforced that adults must be 21 years old or older in order to purchase alcohol. Meanwhile, some parts of the U.S. have also implemented a mandated age of 21 years or older to purchase tobacco. The U.S. government strongly believed that if the minimum age requirement was raised to 21 it would reduce the number of young adults drinking and smoking. However, Mike Males, a Senior Researcher for San Francisco's Center on Juvenile and Criminal Justice, highlighted that changing the age limit has little to no effect in the reduction of underage users. Additionally, teenagers are more likely to obtain their supply from an illegal source and consequently, teenagers are more likely to drink or smoke in excess. Similarly, as the legal cannabis market begins to take off, lawmakers are approaching the industry with caution. In U.S. states where cannabis is legal for adult-use, only adults 21 years old and over are allowed to purchase any cannabis-based products. On the other hand, Canada allows consumers 18 years old and older (19 years old in some provinces) to purchase cannabis-based products. The age difference between the two countries allows Canada to minimize the illicit trade market. Similarly, the United States setting the legal age at 18 years old would add a whole new demographic of young adults to the market, expanding the market penetration even further. And according to data compiled by Imarc Group, the North American legal cannabis market is expected to reach USD 35 Billion by 2023 from USD 8 Billion in 2017. Additionally, the market is expected to register a healthy CAGR of 28% throughout the forecast period. Global Payout, Inc. (OTC: GOHE), The Supreme Cannabis Company, Inc. (OTC: SPRWF) (TSX: FIRE), Emerald Health Therapeutics Inc. (OTC: EMHTF) (TSX-V: EMH), 22nd Century Group, Inc. (NYSE: XXII), Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI)
Patients Forego Traditional Prescriptions in Favor of Cannabis
- PR Newswire - Tue Oct 8, 8:00AM CDT
PR Newswire - CMTX
Tue Oct 8, 8:00AM CDT
Prescription drugs range from depressants and opioids to stimulants and are generally known to be highly addictive and capable of causing severe harm to the heart, brain, and liver with repeated use. Consequently, if patients abuse prescription drugs, it can ultimately prove to be life-threatening. Now, the concern over the growing epidemic of prescription drug abuse has led medical institutions and professionals to reconsider what patients are prescribed. Notably, in regions where cannabis is legalized for medical purposes, more and more patients are beginning to use cannabis as an alternative to pharmaceutical medications. Specifically, Canada has witnessed its medical patient user base grow significantly over the past several years. There were 296,702 patients registered under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) program as of March 2018. Compared to the same period a year prior, the number of registered patients grew by 76.9%. The robust growth reflects how rapidly the user base is growing as more people turn to cannabis as a medical alternative. Moreover, the global user base is projected to continually grow as well as more countries begin to implement medical cannabis programs. And according to data compiled by MarketsandMarkets, the global cannabis market is projected to grow from USD 10.3 Billion in 2018 to USD 39.4 Billion by 2023. Furthermore, the market is anticipated to grow at a CAGR of 30.7% during the forecast period. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), The Supreme Cannabis Company, Inc. (OTC: SPRWF) (TSX: FIRE), Auxly Cannabis Group Inc. (OTC: CBWTF) (TSX-V: XLY), Planet 13 Holdings Inc. (OTC: PLNHF) (CSE: PLTH), Harvest Health & Recreation Inc. (OTC: HRVSF) (CSE: HARV),
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.83 +1.20% increase
on 10/18/19
Period Open:1.40
Price movement based on the high, low and last over the given period.
1.42 -40.85% decrease
on 09/19/19
-0.56 (-40.00%) decrease
since 09/18/19
3-Month 0.83 +1.20% increase
on 10/18/19
Period Open:1.49
Price movement based on the high, low and last over the given period.
1.74 -51.72% decrease
on 08/20/19
-0.65 (-43.62%) decrease
since 07/18/19
52-Week 0.83 +1.20% increase
on 10/18/19
Period Open:1.98
Price movement based on the high, low and last over the given period.
2.36 -64.41% decrease
on 02/04/19
-1.14 (-57.58%) decrease
since 10/18/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).